Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
What is your approach to the management of severe tricuspid regurgitation secondary to endocarditis with the presence of an RV pacemaker lead in place?
Related Questions
What could potentially account for new increases in NTproBNP or BNP levels in patients immediately post-TEER of mitral and/or tricuspid valves without clinical signs of heart failure and/or volume overload?
Following cardiac MRI, what imaging modality would you consider to further evaluate mild aortic regurgitation (regurgitant fraction on cardiac MRI of 26%) and mild to moderate mitral regurgitation secondary to mild bi-leaflet mitral valve prolapse (RF 30%) with low-normal LVEF and incomplete RBBB?
Would you consider an inpatient Mitraclip for patients with severe MR and severely reduced LVEF who have been turned down/high risk for surgery if there were ongoing challenges with afterload reduction and transitioning to intermittent dialysis due to recurrent flash pulmonary edema?
What is your preferred single antiplatelet agent to use when combined with a DOAC for a patient with atrial fibrillation who is now 1 year post-TAVR?
For asymptomatic, incidentally found Lambl's excrescence, should long-term surveillance imaging be considered and if so, how often should repeat imaging be ordered?
What are your top takeaways from ACC 2024?
What factors would influence your decision to use or avoid heparin bridging in patients with mechanical heart valves resuming anticoagulation after intracerebral hemorrhage?
What is the optimal anti-platelet/anticoagulant strategy and duration following a left atrial appendage occlusion with a watchmen device and is a CTA good enough to assess if the device is well seated and without any peri device leaks?
How long should patients with atrial fibrillation who are already on systemic anticoagulation and are status post TAVR and PCI 6 months ago remain on Plavix?
How do you decide the right time for MitraClip intervention in patients with symptomatic heart failure and severe mitral regurgitation who are on maximally tolerated GDMT?
